Buyer Guide,compounding pharmacies can no longer make and sell semaglutide injections

The question of is semaglutide being discontinued has been a significant concern for many individuals relying on this medication for diabetes management and weight loss. Recent developments, particularly concerning the semaglutide shortage, have led to confusion, especially regarding compounded semaglutide. However, the primary concern isn't a discontinuation of the drug itself, but rather a shift in its availability and regulatory landscape.

The U.S. Food and Drug Administration (FDA) officially declared the semaglutide shortage on Feb 21, 2025, marking a turning point in the availability of both the branded versions and their compounded counterparts. This declaration meant that the drug, widely known under brand names like Ozempic and Wegovy, was no longer experiencing widespread supply issues. According to the FDA, semaglutide was officially declared to no longer be on shortage on that date. Novo Nordisk, the manufacturer, stated that all semaglutide doses are now being “continuously shipped” to wholesalers and are “meeting or exceeding expected U.S. demand.”

However, this resolution of the shortage has had a direct impact on compounded semaglutide. For a period, compounding pharmacies were permitted to create their own versions of semaglutide and other GLP-1 drugs due to the official shortage. This allowed patients to access more affordable alternatives. But with the shortage officially over, regulatory changes have taken effect. The FDA has been actively taking steps to restrict the production and sale of these compounded versions.

A key development is the FDA's decision to remove semaglutide from its drug shortage list. This action has significant implications for compounding pharmacies. As of February 2025, semaglutide was removed from the list, and consequently, compounding pharmacies were required to cease production of their own versions. The FDA has been issuing directives, and by April 22, 2025, many state-licensed pharmacies were mandated to stop making most compounded semaglutide (copies of Novo Nordisk's Wegovy and Ozempic). Furthermore, after May 22, compounding pharmacies can no longer make and sell semaglutide injections. This means that any compounded GLP-1 ban update signifies a tightening of regulations around these alternative formulations.

The FDA's stance is that the semaglutide shortage over and that the drug is now readily available through its approved manufacturers. This has led to a situation where compounded semaglutide is only available in certain situations, primarily those that fall within specific grace periods or exemptions. For instance, the grace periods for compounded semaglutide and tirzepatide injections have ended as of May 2025.

The FDA's recent decision to remove semaglutide from the drug shortage list marks a significant shift for compounding pharmacies. This regulatory action has led to restrictions, and in many cases, a halt in the sale of off-brand Ozempic and other GLP-1 drugs. The FDA halts sales of compounded semaglutide as a result of updated guidance. While the official shortage may be resolved, the availability of compounded versions is significantly reduced.

For patients who have been using compounded versions, this presents a challenge. The FDA's actions are partly driven by safety concerns and the desire to ensure patients receive authentic, FDA-approved medications. Some healthcare professionals are exploring alternative options for patients, and Wegovy alternatives to consider for weight loss are becoming a topic of discussion.

In summary, while the question is semaglutide being discontinued might arise, the reality is that the primary concern is the regulation of compounded versions. The official semaglutide shortage has been declared over by the FDA, and the drug is no longer listed on the FDA website as being in shortage. This has led to restrictions on compounding pharmacies, meaning that semaglutide are no longer allowed to be produced and sold in the same manner as before. The semaglutide and tirzepatide shortages are officially over, and patients should consult with their healthcare providers to navigate the current availability and discuss approved treatment options.